Ribavirin Injection
Ribavirin injection, indications for antiviral drugs. For respiratory syncytial virus caused by viral pneumonia and bronchitis.
Pharmacology broad spectrum antiviral drugs. It can inhibit the growth of respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus and other viruses in vitro. This product does not change virus adsorption, invasion and shelling, and does not induce interferon production. After entering the infected cells, the drug rapidly phosphorylates, and its product acts as a competitive inhibitor of viral synthetase, which inhibits inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, which results in the decrease of guanosine triphosphate in cells, damages the synthesis of viral RNA and protein, and inhibits the replication and transmission of virus. It may also have immune effect and neutralizing antibody effect on respiratory syncytial virus.
Toxicological animal experiments showed that the product could induce benign tumors of breast, pancreas, pituitary and adrenal gland, but its carcinogenicity to human body was not confirmed. However, the effect of drugs on the fetus was not found in primate animal experiments. Mice, rats and monkeys were given ribavirin orally at doses of 30, 36 and 120 mg / kg or for more than 4 weeks (equivalent to human dose: 4.8, 12.3 and 111.4 mg / kg for children weighing 5 kg, or 2.5, 5.1 and 40 mg / kg for adults with body weight of 60 kg) for more than 4 weeks.
Audited Supplier 
){kind=link}